ArticleFrontiers in pharmacology2026
Kaempferol in inflammatory bowel disease: regulating intestinal epithelial-fibroblast crosstalk.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Inflammatory bowel disease (IBD) has an intricate pathophysiology that greatly impacts patients' quality of life. Wumei Wan, a traditional Chinese medicinal formulation, exhibits specific therapeutic effects on IBD. Kaempferol (KF), an active ingredient in Wumei Wan, may significantly contribute to IBD. Methods: A 2% DSS-induced chronic colitis mouse model was established, randomly divided into six groups and treated with KF. Relevant indicators of chronic colitis were measured, including body weight, Disease Activity Index (DAI), colon length, histological alterations, as well as indicators of inflammatory factors, fibrosis, intestinal barrier function, hepatic and renal function, and oxidative stress. TNF-α was employed to stimulate colonic epithelial cells in cell studies. After KF intervention, cytotoxicity, transforming growth factor-β1 (TGF-β1), and cell survival were observed to investigate its impact on IBD. The HT29/CCD-18Co medium with TNF-α/TNF-α+KF was co-cultured with CCD-18Co/HT29 cells, and a cell line with heme oxygenase 1 (HMOX1) silencing/overexpression was generated to explore the impact of KF on intestinal epithelial cell-fibroblast crosstalk. Results: Discussion: Collectively, KF mitigates IBD by modulating intestinal epithelial-fibroblast interaction, suppressing inflammatory responses, reducing intestinal fibrosis, and increasing intestinal mucosal barrier function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.